BS Opinion: The Challenges of the Pharma Sector in Regulatory Capacity
BS Opinion: The Challenges of the Pharma Sector in Regulatory Capacity
India's pharmaceutical industry has achieved an extraordinary scale, standing as the third-largest global producer by volume. However, as per BS Opinion, the pharma sector is encountering regulatory capacity constraints that impede its ability to scale further. Despite supplying around 20 percent of global generic medicines and exporting $30.5 billion of pharmaceuticals in FY25, India only ranks eleventh in pharmaceutical exports by value, with a mere 3 percent share globally.
The Need for Innovation in Pharmaceuticals
To overcome these constraints, the pharma industry must prioritize innovation. The focus should shift towards complex generics, biologics, and biosimilars. This pivot is essential for propelling India's pharmaceutical ambitions to new heights.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.